Monoclonal antibody therapy with ciclosporin and steroids in nonmatched cadaveric renal transplants.
Thirty-six ciclosporin-prednisone-treated recipients of nonmatched cadaver renal allografts were given a course of Orthoclone OKT3 monoclonal antibody for steroid-resistant cell-mediated rejection. Although side effects were common, only 2 patients had to be withdrawn from therapy and there were no deaths related to therapy. Twenty-three (63.9%) allografts were rescued with OKT3 therapy and 21 (58.3%) of the grafts have continued to function well. We conclude that OKT3 is an effective agent for the treatment of steroid-resistant cell-mediated rejection and that rebound rejection can be prevented in most patients if adequate therapy with ciclosporin-prednisone is maintained.
Gordon
R D
RD
Starzl
T E
TE
Fung
J J
JJ
Iwatsuki
S
S
Esquivel
C O
CO
Tzakis
A
A
Todo
S
S
D000293:Adolescent; D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D002648:Child; D002986:Clinical Trials as Topic; D003524:Cyclosporins / Q000008:administration & dosage*; D004064:Digestive System / Q000187:drug effects; D004359:Drug Therapy, Combination; D005260:Female; D006084:Graft Rejection; D006801:Humans; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage*
D000911:Antibodies, Monoclonal; D003524:Cyclosporins; D011241:Prednisone